NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status (Descending) |
---|---|---|---|---|---|---|---|---|---|---|---|
00409-0021-03 | 00409-0021 | PEMETREXED | PEMETREXED | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Feb. 1, 2023 | In Use | |
00409-0004-04 | 00409-0004 | PEMETREXED | PEMETREXED | 1.0 g/40mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Feb. 1, 2023 | In Use | |
00409-0020-02 | 00409-0020 | PEMETREXED | PEMETREXED | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Feb. 1, 2023 | In Use | |
00480-1241-28 | 00480-1241 | Lenalidomide | Lenalidomide | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | March 8, 2023 | In Use | |
00480-1245-21 | 00480-1245 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | March 8, 2023 | In Use | |
00781-3516-75 | 00781-3516 | METHYLPREDNISOLONE ACETATE | METHYLPREDNISOLONE ACETATE | 80.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intralesional, Intramuscular, Intrasynovial, Soft Tissue | Feb. 8, 2023 | In Use | |
00527-1242-02 | 00527-1242 | Fludarabine Phosphate | Fludarabine Phosphate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Dec. 31, 2019 | In Use | |
00517-4300-01 | 00517-4300 | Paclitaxel | Paclitaxel | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | May 2, 2023 | In Use | |
10135-0774-01 | 10135-0774 | Prednisone | Prednisone | 1.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb. 1, 2023 | In Use | |
10135-0775-01 | 10135-0775 | Prednisone | Prednisone | 2.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb. 1, 2023 | In Use |
Found 10,000 results in 10 milliseconds — Export these results